These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 15574998)

  • 1. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice.
    Fan Q; Liao J; Kobayashi M; Yamashita M; Gu L; Gohda T; Suzuki Y; Wang LN; Horikoshi S; Tomino Y
    Nephrol Dial Transplant; 2004 Dec; 19(12):3012-20. PubMed ID: 15574998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.
    Liao J; Kobayashi M; Kanamuru Y; Nakamura S; Makita Y; Funabiki K; Horikoshi S; Tomino Y
    J Nephrol; 2003; 16(6):841-9. PubMed ID: 14736011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB.
    Onozato ML; Tojo A; Goto A; Fujita T; Wilcox CS
    Kidney Int; 2002 Jan; 61(1):186-94. PubMed ID: 11786100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse.
    Giunti S; Calkin AC; Forbes JM; Allen TJ; Thomas MC; Cooper ME; Jandeleit-Dahm KA
    Am J Physiol Renal Physiol; 2010 Sep; 299(3):F528-35. PubMed ID: 20554645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice.
    Tanimoto M; Gohda T; Kaneko S; Hagiwara S; Murakoshi M; Aoki T; Yamada K; Ito T; Matsumoto M; Horikoshi S; Tomino Y
    Metabolism; 2007 Feb; 56(2):160-7. PubMed ID: 17224327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies.
    Liu H; Kitazato KT; Uno M; Yagi K; Kanematsu Y; Tamura T; Tada Y; Kinouchi T; Nagahiro S
    J Hypertens; 2008 Jul; 26(7):1435-45. PubMed ID: 18551021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of albuminuria by angiotensin receptor blocker beyond blood pressure lowering: evaluation in megsin/receptor for advanced glycation end products/inducible nitric oxide synthase triple transgenic diabetic nephropathy mouse model.
    Ohtomo S; Ito M; Izuhara Y; Van Ypersele De Strihou C; Miyata T
    Nephrology (Carlton); 2008 Dec; 13(6):517-21. PubMed ID: 18363646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of advanced glycation end products by candesartan in patients with diabetic kidney disease--a dose-response relationship study.
    Saha SA; LaSalle BK; Clifton GD; Short RA; Tuttle KR
    Am J Ther; 2010; 17(6):553-8. PubMed ID: 19829095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glomerular changes in the KK-Ay/Ta mouse: a possible model for human type 2 diabetic nephropathy.
    Ito T; Tanimoto M; Yamada K; Kaneko S; Matsumoto M; Obayashi K; Hagiwara S; Murakoshi M; Aoki T; Wakabayashi M; Gohda T; Funabiki K; Maeda K; Horikoshi S; Tomino Y
    Nephrology (Carlton); 2006 Feb; 11(1):29-35. PubMed ID: 16509929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension.
    Yu Y; Fukuda N; Yao EH; Matsumoto T; Kobayashi N; Suzuki R; Tahira Y; Ueno T; Matsumoto K
    Am J Hypertens; 2008 Jan; 21(1):72-7. PubMed ID: 18091747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.
    Alter ML; Ott IM; von Websky K; Tsuprykov O; Sharkovska Y; Krause-Relle K; Raila J; Henze A; Klein T; Hocher B
    Kidney Blood Press Res; 2012; 36(1):119-30. PubMed ID: 23171828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nifedipine, a calcium-channel blocker, attenuated glucose intolerance and white adipose tissue dysfunction in type 2 diabetic KK-A(y) mice.
    Iwai M; Kanno H; Inaba S; Senba I; Sone H; Nakaoka H; Horiuchi M
    Am J Hypertens; 2011 Feb; 24(2):169-74. PubMed ID: 20847723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on beta-cell function and morphology in db/db mice.
    Shao J; Iwashita N; Ikeda F; Ogihara T; Uchida T; Shimizu T; Uchino H; Hirose T; Kawamori R; Watada H
    Biochem Biophys Res Commun; 2006 Jun; 344(4):1224-33. PubMed ID: 16650382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor receptor-2 and low affinity VEGF binding sites on human glomerular endothelial cells: Biological effects and advanced glycosilation end products modulation.
    Pala L; Cresci B; Manuelli C; Maggi E; Yamaguchi YF; Cappugi P; Rotella CM; Giannini S
    Microvasc Res; 2005 Nov; 70(3):179-88. PubMed ID: 16271941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways.
    Liu XP; Pang YJ; Zhu WW; Zhao TT; Zheng M; Wang YB; Sun ZJ; Sun SJ
    Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):287-96. PubMed ID: 19018797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II receptor blocker inhibits abnormal accumulation of advanced glycation end products and retinal damage in a rat model of type 2 diabetes.
    Sugiyama T; Okuno T; Fukuhara M; Oku H; Ikeda T; Obayashi H; Ohta M; Fukui M; Hasegawa G; Nakamura N
    Exp Eye Res; 2007 Sep; 85(3):406-12. PubMed ID: 17678894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amelioration of cognitive impairment in the type-2 diabetic mouse by the angiotensin II type-1 receptor blocker candesartan.
    Tsukuda K; Mogi M; Li JM; Iwanami J; Min LJ; Sakata A; Fujita T; Iwai M; Horiuchi M
    Hypertension; 2007 Dec; 50(6):1099-105. PubMed ID: 17968000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic diabetic nephropathy: role of inducible nitric oxide synthase.
    Trachtman H; Futterweit S; Pine E; Mann J; Valderrama E
    Pediatr Nephrol; 2002 Jan; 17(1):20-9. PubMed ID: 11793130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats.
    Chung S; Park CW; Shin SJ; Lim JH; Chung HW; Youn DY; Kim HW; Kim BS; Lee JH; Kim GH; Chang YS
    Nephrol Dial Transplant; 2010 Feb; 25(2):389-99. PubMed ID: 19749146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension.
    Ono H; Minatoguchi S; Watanabe K; Yamada Y; Mizukusa T; Kawasaki H; Takahashi H; Uno T; Tsukamoto T; Hiei K; Fujiwara H
    Hypertens Res; 2008 Feb; 31(2):271-9. PubMed ID: 18360047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.